Danaher Corporation

ticker: DHR step: 01 generated: 2026-05-12 source: quick-research

Danaher Corporation (DHR) — Business Overview

Business Description

Danaher is a leading global designer + manufacturer of high-quality scientific instruments and consumables across three segments: Biotechnology (Cytiva + Pall — bioprocessing), Life Sciences (Leica Microsystems, SCIEX — research instruments), and Diagnostics (Beckman Coulter, Cepheid — clinical lab + molecular). Powered by the Danaher Business System (DBS), the proprietary continuous improvement methodology. CEO Rainer Blair has been in the role since September 2020. In September 2023, Danaher spun off Environmental & Applied Solutions as Veralto. Pending $9.9B Masimo acquisition adds connected medical devices.

Revenue Model

• Biotechnology (~40% of revenue): Bioprocessing consumables + equipment via Cytiva (acquired 2020 GE Biosciences for $21B) + Pall — supports biologic drug manufacturing, vaccines, cell/gene therapy
• Diagnostics (~35%): Clinical lab instruments (Beckman Coulter) + point-of-care molecular (Cepheid)
• Life Sciences (~25%): Microscopy (Leica), mass spectrometry (SCIEX), liquid handling (Beckman Coulter), centrifugation
• ~75-80% recurring revenue (consumables + services) — exceptional for industrial conglomerate

Products & Services

Biotechnology (Cytiva + Pall)

• Bioprocessing consumables: Bioreactors, filters, chromatography resins, single-use technologies
• Cytiva-branded equipment + AKTA chromatography systems
• Pall filtration: Industrial + biopharma filtration
• 75% of Cytiva exposure is monoclonal antibody (mAb) production

Diagnostics

• Cepheid: GeneXpert PCR system + cartridges — respiratory, GI, HIV, TB, oncology
• Cepheid Xpert GI Panel (new FDA clearance): 11-pathogen GI test
• Beckman Coulter Diagnostics: Hematology, urinalysis, chemistry, immunoassay
• Radiometer: Blood gas analyzers
• HemoCue: Point-of-care testing

Life Sciences

• Leica Microsystems: Light + electron microscopes, slides scanners
• SCIEX: Mass spectrometry, capillary electrophoresis
• Beckman Coulter Life Sciences: Flow cytometry, centrifugation, liquid handling
• Phenomenex: Chromatography consumables
• IDT (Integrated DNA Technologies): Custom DNA synthesis

Pending Acquisitions

• Masimo (announced 2026): $9.9B for connected medical devices — concerning to bears on "diworsification"

Customer Base & Go-to-Market

• Biopharma + Pharma manufacturers: Top global biopharma companies for bioprocessing
• Hospitals + clinical labs: Diagnostics products
• Academic + government research: Life Sciences instruments
• Customer concentration: Top 10 customers ~20% of revenue (diversified)
• Geographic mix: ~45% NA, ~30% Europe, ~25% APAC (China specifically ~10%; weak in 2024-2025 due to VBP)

Competitive Position

Danaher has #1 or #2 positions in most addressable markets: #1 bioprocessing (Cytiva ~25% market share, ahead of Sartorius + Thermo Fisher in some sub-segments), #1 point-of-care molecular diagnostics (Cepheid), top-3 in clinical chemistry (Beckman Coulter). Moats: (1) DBS continuous improvement = sustained margin expansion, (2) bioprocessing consumables "razor-and-blade" recurring revenue, (3) Cepheid installed base + cartridge stickiness, (4) capital allocation track record. Competitors: Sartorius (bioprocessing), Thermo Fisher Scientific (broad), Agilent (life sciences instruments), Roche Diagnostics (clinical).

Key Facts

• Founded: 1969 (originally a real estate investment trust); acquired/transformed into industrial conglomerate via DBS
• Headquarters: Washington, DC
• Employees: ~63,000
• Exchange: NYSE
• Sector / Industry: Health Care / Life Sciences Tools & Services
• Market Cap: ~$155B (May 2026)
• CEO: Rainer M. Blair (since September 2020)
• Chairman: Mitchell P. Rales (co-founder)
• Dividend: $1.16 annual ($0.29 quarterly)
• Recent: Veralto spin-off (Sept 2023); pending Masimo acquisition $9.9B

ticker: DHR step: 04 generated: 2026-05-12 source: quick-research

Danaher Corporation (DHR) — Financial Snapshot

Income Statement Summary (post-Veralto spin-off Sept 2023)

Segment Performance (FY2025)

Q1 2026 Highlights

Key Product Detail

Cash Flow & Balance Sheet (FY2025)

Key Ratios (approximate, May 2026)

• P/E (forward): ~27x | EV/EBITDA: ~17x | Dividend Yield: ~0.6%
• ROIC: ~10% (pre-Masimo)
• FCF margin: ~22%

Growth Profile

Q1 2026 marked an inflection: bioprocessing equipment orders +30% YoY (first positive in nearly 2 years). Consumables low double-digit growth. Management raised FY26 EPS guidance on bioprocessing momentum. Q1 FCF conversion 146% — exceptional. Bear case "bioprocessing winter" appears to be ending. Diagnostics still drag (China VBP, normalized respiratory).

Forward Estimates

• FY2026E Revenue: ~$26B (+5-6%)
• FY2026E Adj EPS: ~$8.50 (+9%)
• FY2027E EPS: ~$9.50 (+12%)
• FY2026 Bioprocessing core growth: high-single-digit (mgmt guide)
• Long-term EPS growth target: 10-12%

Capital Return

• Dividend $1.16 annual (~$0.9B paid)
• Buybacks: $5-7B annual run rate (varies with M&A)
• Total return ~3-5%
• Masimo pending $9.9B acquisition will constrain near-term buybacks

ticker: DHR step: 12 generated: 2026-05-12 source: quick-research

Danaher Corporation (DHR) — Investment Catalysts & Risks

Bull Case Drivers

1. Bioprocessing inflection — equipment orders +30% YoY — Q1 2026 marked the first quarter of positive YoY equipment order growth in nearly 2 years. Consumables low double-digit growth. Management raised FY26 EPS guidance on this momentum. Bears called this the "bioprocessing winter" — that winter is ending, and management guides high-single-digit core growth in bioprocessing for FY26.

2. mAb production scale = durable consumables tailwind — 75% of Cytiva exposure is monoclonal antibody (mAb) manufacturing. Global mAb production continues compounding as more biologics are approved (immunology, oncology, cardiovascular). Consumables follow installed bioreactor capacity — multi-year recurring revenue secular tailwind.

3. Cepheid + diagnostics resilient — Cepheid GI Panel new FDA clearance opens new market. Cepheid respiratory targeting $1.7B FY26. While China VBP and lower COVID create near-term drag, the underlying franchise is stable. Free cash flow conversion at 146% in Q1 2026 shows operating leverage even at modest growth.

4. DBS continuous improvement + capital allocation — Danaher Business System has driven decades of margin expansion + ROIC. Track record of accretive M&A (GE Biosciences/Cytiva $21B, Pall, Beckman Coulter, Cepheid). 146% FCF conversion + $5.3B FCF base allows continued capital deployment.

Bear Case Risks

1. Masimo "diworsification" risk — $9.9B Masimo acquisition (announced 2026) is bear concern. Masimo is connected medical devices — somewhat outside Danaher's core bioprocessing/diagnostics/life sciences. Bears worry Danaher is "buying revenue" to offset slow bioprocessing recovery. Integration + valuation discipline questions.

2. NIH funding uncertainty + academic weakness — Management cited US funding uncertainty (especially academic/university research) as weakening Life Sciences outlook. Continued reductions in NIH + university research funding under Trump administration could materially impact Leica + SCIEX academic exposure.

3. China VBP drag + Diagnostics weakness — China Diagnostics core revenue down high-single-digit. China VBP impact accelerated to $150M annual (vs prior $50M expectation). If VBP expands to additional Cepheid + Beckman Coulter categories, headwind expands materially.

4. Stock -24% in 2026, -4% TTM — DHR fell ~24% in 2026 YTD on bioprocessing winter concerns + Masimo concerns. While Q1 marked inflection, bears note that stock has been falling for several years despite "biological engine" thesis. If bioprocessing recovery proves shallow, multiple compression continues.

Upcoming Events

• Q2 2026 earnings (July 2026) — Bioprocessing order growth durability test; Masimo deal commentary
• Q3 2026 earnings (October 2026) — Diagnostics recovery (Cepheid respiratory season); China outlook
• Masimo deal close — Expected mid-to-late 2026
• Cepheid GI Panel commercial ramp — New product launch metrics
• Bioprocessing capacity additions at customers — Drives Cytiva equipment orders

Analyst Sentiment

Sell-side consensus is Hold / Moderate Buy with average price targets in the $230-260 range vs. recent ~$215 trading levels (~7-21% upside). Bulls (Insider Monkey, Simply Wall St "biological engine") cite bioprocessing inflection + Q1 momentum + DBS. Bears focus on Masimo integration + NIH funding. Stock has underperformed peers (TMO, ABT) over past 2 years — bioprocessing recovery is the swing factor for re-rating.

Research Date

Generated: 2026-05-12